FDA Widened Abilify Scope To Admit Generics, Otsuka Says
Otsuka Pharmaceutical Co. slammed the U.S. Food and Drug Administration Tuesday for expanding the scope of its antipsychotic drug Abilify to treat Tourette's syndrome in patients of all ages rather than...To view the full article, register now.
Already a subscriber? Click here to view full article